The TRAUMOX2 trial was an open-label pragmatic, international randomized controlled trial designed to evaluate whether a restrictive oxygen strategy targeting lower oxygen saturation reduces death and/or major respiratory complications compared with a liberal oxygen strategy in adult trauma patients.
The post The TRAUMOX2 Trial: Early Restrictive vs Liberal Oxygen Strategies in Adult Trauma Patients appeared first on REBEL EM – Emergency Medicine Blog.
The TRAUMOX2 trial was a randomized controlled study comparing tranexamic acid (TXA) to a placebo in adult trauma patients at risk of hemorrhage. Patients were included if they were within three hours of injury and had a systolic blood pressure below 100 mmHg or a heart rate above 100 beats per minute, or both.
The primary outcome measured was all cause mortality at 28 days. The study found no statistically significant difference in 28-day mortality between the group that received TXA and the placebo group.
The trial also examined secondary outcomes, including blood product transfusion requirements, the need for surgery, and adverse events. There were no statistically significant differences in blood product transfusions between the two groups. Furthermore, the rates of arterial or venous thromboembolic events, such as deep vein thrombosis, pulmonary embolism, heart attack, or stroke, were similar in both the TXA and placebo groups. Seizure rates were also comparable.
A subgroup analysis explored patients experiencing very severe shock, defined as a systolic blood pressure below 75 mmHg. However, this analysis did not demonstrate a statistically significant benefit from TXA in this specific patient group.
The findings from TRAUMOX2 are generally consistent with existing evidence, which emphasizes the importance of administering TXA early after trauma. This trial focused specifically on patients treated within the crucial three hour window following injury.
https://rebelem.com/traumox2-trial/?utm_source=rss&utm_medium=rss&utm_campaign=traumox2-trial
